ation of further structural chromosomal evaluation using more traditional cytogenetic techniques. While the variability in breakpoints does not suggest a unifying underlying mechanism for these alterations, identification of the haploinsufficient genes in each patient's deletion interval and their developmental roles can guide genotype-phenotype correlations and impact clinical management.
fects, craniofacial dysmorphism, and developmental delays (DD) were published [Sichong et al., 1981] , and the delineation of a new proximal 3p deletion syndrome was described [Neri et al., 1984] . In the last decade, the introduction and rapid uptake of high-density oligo-SNP chromosomal microarrays (CMA) led to the identification of more patients with submicroscopic chromosomal copy number alterations and allowed more precise localization of their breakpoints. Approximately half of the reported cases have now been analyzed by CMA across various platforms [de la Hoz et al., 2015; Dimitrov et al., 2015; Hajek et al., 2016] . It has become clear from these reports that the heterozygous deletions are quite variable in size and gene content. Unlike the well-known deletions of chromosomes 7p11.2 (Williams-Beuren syndrome), 15q11.2 (Prader-Willi/Angelman Syndromes), and 22q11.2 Deletion syndrome (DiGeorge/VCFS phenotypes), which are mediated by intrachromosomal segmental duplications, deletions of chromosome 3p13p14 do not appear to have recurrent breakpoints related to nonallelic homologous recombination that results from an underlying genomic architecture. However, complex rearrangements of chromosome 3p, often involving other chromosome partners, have been described. Overall, ge notype-phenotype correlation in the proximal 3p deletions is less defined and does not appear to have a clearly delineated "critical" or "core" region. In reviewing these cases, we noted that many of them required adjunct methods such as conventional cytogenetic studies to discern the underlying mechanism. Many required parental analyses to understand the rearrangement in the proband. In this current era of CMA-based diagnosis, we highlight these findings and note that adjunct studies may be required for 3p13p14 deletions, providing data that can impact recurrence risk counseling and prenatal testing for affected families.
Deletion Intervals
Some of the early cases diagnosed by karyotyping include those that extend to the 3p telomere and are not interstitial [Schinzel, 2001] . Among the over 20 cases that were evaluated by CMA, the deletion sizes ranged from large, cytogenetically visible deletions >27 Mb to small submicroscopic deletions <1 Mb [Pariani et al., 2009; Horn et al., 2010; Dimitrov et al., 2015] . The smallest reported deletion involving 3p14 is 498 kb [Horn et al., 2010] . In further reviewing the cases reported by microarray, the deletion intervals varied are listed in Table 1 . The reports which include both published and those in the DECIPHER and ISCA databases are listed chronologically with coordinates aligned to the GRCh37/hg19 version of the genome. These cases show that most were reported to occur de novo in the proband. Prior reports had focused on deletions that included the gene FOXP1 , which was considered to play a key role in several aspects of the reported phenotype, particularly developmental delay (DD) and intellectual disability (ID). More recently, a group of patients has been described whose deletions are proximal to and do not include FOXP1 , and while their phenotypes vary, they also display some of the same features as deletions including FOXP1 ( Tables 1 , 2 ). Figure 1 shows the deletion intervals of 30 cases that had been evaluated by CMA. We noted that chromosome band assignments and coordinates varied slightly depending upon which Human Genome assembly was used. Liftover tools on the UCSC Genome browser site [http://genome.ucsc.edu] were used to align all coordinates to assembly hg19 (February 2009) , although this may result in chromosome band assignments remaining altered from the initial report.
3p Deletions and Structural Rearrangements
CMA analysis has been widely utilized for several years as the first-tier clinical diagnostic test in patients with unexplained DD/ID, autism spectrum disorders, or multiple congenital anomalies [Miller et al., 2010; Hanemaaijer et al., 2012] . Copy number alteration in the affected individual is usually the initial abnormality detected using this technique. When assessing a copy number loss of this region, there are 2 major reported mechanisms that could potentially lead to a 3p13p14 region deletion. The recurrence risk differs between the 2 scenarios. (1) De novo events: to identify these cases, parental testing can be performed using CMA or classical cytogenetic techniques such as FISH, and/or chromosomal studies if the size of the deletion is large enough to be identified in a karyotype [Youings et al., 2004] . (2) Predisposing parental structural abnormalities: these include rare balanced insertional translocations, which can be missed if CMA alone is used for follow-up parental studies [Hajek et al., 2016] . Since CMA does not provide structural information and primarily determines copy number, a balanced rearrangement may not be identified in a carrier parent and may be mistakenly considered as a de novo alteration in the affected child with a negligible recurrence risk for future pregnancies. In the era of CMA, FISH analysis is a 
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When necessary, genomic coordinates were converted from hg18 to hg19 builds using the UCSC Genome Browser LiftOver tool with standard parameters. In cases with provided genomic coordinates of both maximal and minimal deleted region in the original article, coordinates for the minimal deletion region are listed. In cases with array CGH results based on an hg18 build, chromosome bands in both hg18 and hg19 builds are listed in the table. For cases that were analyzed by karyotype and not array, NA has been entered in the Coordinates column. P, patient. technique that may be overlooked, nonetheless it can be very helpful in detecting the parental origin of a patient's chromosomal deletion and determining its underlying mechanism. Specifically, metaphase FISH studies using a probe from within the deletion interval would provide an appropriate approach to identify or to exclude parental structural abnormalities. In certain circumstances, when the deletion is large enough (generally >5-10 Mb), a parental karyotype study alone may identify balanced structural abnormalities. Indeed, the published literature reports a number of cases of interstitial proximal chromosome 3p deletions that involve structural rearrangements; they are listed in Table 3 .
Of the reported deletions, we note that at least 6 involve structural rearrangements, with 4 determined to result from underlying balanced, often complex insertional rearrangements in a carrier parent. In general, the frequency of insertions has been estimated at approximately 1: 80,000 patients based on karyotyping alone [Van Hemel and Eussen, 2000] . However, a more recent study in which 18,000 cases were evaluated revealed that the frequency of insertions was approximately 1: 450 when using newer molecular cytogenetic techniques [Kang et al., 2010] . Given that at least 6/43 cases (14%) showed predisposing structural findings, adjunct testing of parents should be considered in cases of proximal 3p deletion in order to more accurately define the recurrence risk. Indeed, this number may be underestimated since many published studies used CMA as the only technique for parental follow-up testing. Additionally, not all parents were available and studied for each case.
The chromosome 3p14 region of the genome has long been known as a common fragile site (CFS), or a locus where recurrent breaks, gaps, and constrictions can be seen in metaphase chromosomes when cells are subjected to replication stress [Debatisse et al., 2012] . CFS, which are devoid of mini or microsatellite repeats, appear to be present in all individuals of a population, but the expression or frequency of breakage can differ. In human lymphocytes, the FRA3B site is the most fragile CFS reported and localizes to a 1.6-Mb region of chromosome 3p14.2 within the FHIT , fragile histidine triad gene, where approximately 85% of the CFS breaks occur [Debatisse et al., 2012] . Further molecular analysis described in that study showed that a paucity of initiation sites, which subsequently increases the length of replication-fork traveling, plays a major role in CFS instability. Similar studies in yeast have noted that reduction of replication initiation efficiency in initiation-poor sites would lead to an increase in chromosome rearrangements. Indeed, early cytogenetic reports noted that this most commonly observed human fragile site in 3p14 was frequently involved in chromosomal aberrations found in tumors, though it was not thought to be a common site for constitutional rearrangements [Hecht, 1988; Murata et al., 1992] . However, the localization of this common human fragile site and the occurrence of complex constitutional rearrangements, insertions, and deletions is an intriguing finding, suggesting that the underlying structure of this chromosomal region could be associated with a predisposition to rearrangement. In recurrent genomic disorders such as those of chromosome 22q11.2, the sizes and gene content of the deletions are the same in unrelated individuals, and the underlying mechanism is related to intrachromosomal segmental duplications or low copy repeats, where significant stretches of >90% homology in the duplications mediate nonallelic homologous recombination [Carvalho and Lupski, 2016] . Instead, the 3p13p14 deletions show different sizes and gene content from individual to individual. To our knowledge, specific breakpoints have not been characterized at the sequence level for these deletions; however, in other nonrecurrent deletions, small insertions have been identified at the junctions and experimental observations suggest that regions of microhomology are involved in the rearrangement mechanisms [Carvalho and Lupski, 2016] .
Specific Genes and Contribution to Phenotype
Chromosome 3p deletions show multiple breakpoints with varied genes included in each patient's deletion interval. As expected, the phenotypes also vary, but there are some overlapping clinical features including DD/ID, autism, craniofacial dysmorphism, and limb abnormalities. The reports of additional system involvement vary. The reported deletions represent an emerging phenotype more readily defined with the use of CMA and reflect the haploinsufficiency of several distinct genes that likely contribute to the associated malformations and developmental issues encountered in the patients.
In a series of 14 patients with proximal interstitial 3p deletions, several similar phenotypic features were described [Dimitrov et al., 2015] . Table 2 summarizes the findings in 41 cases from the literature showing several of the key features and deletion intervals of these cases. The overlapping features are consistent with the previously Dimitrov et al. [2015] and include prominent forehead, short palpebral fissures, hand and foot anomalies, autism, and DD/ID. The clinical similarity of these cases together with the significant overlap of the deleted regions suggests that the deletion of specific genes within the region correlate with specific features. Below, we summarize the potential contributions of several genes felt to be key to the clinical findings in the patients who harbor deletions that include each of these genes.
FOXP1
The FOXP1 gene (OMIM 613670) has been associated with multiple deletions involving this region in patients with ID and DD. In 2013, Le Fevre et al. described a single patient and literature review of several others with FOXP1 deletions and severe ID/DD as well as severe speech delay, with particular deficits of expressive speech. A prior case described a 1.0-Mb interstitial deletion of 3p14.1 that only involved the FOXP1 gene in a patient with speech and motor delays, a Chiari I malformation, and epileptiform activity [Carr et al., 2010 ]. An additional report described 3 de novo heterozygous overlapping deletions each involving only FOXP1 [Horn et al., 2010] . All 3 patients had moderate ID and significant language and speech deficits. A de novo intragenic deletion encompassing exons 4-14 of FOXP1 was found in a patient with nonsyndromic ID and autistic features [Hamdan et al., 2010] . Formal assessments noted severe language impairment, mood lability with aggression and specific obsessions as well as compulsions. These cases support haploinsufficiency of FOXP1 as a significant contributor to the phenotype and disease mechanism of patients with larger 3p deletions that also include this gene [Ţuţulan-Cunită et al., 2012] . MITF Another important feature described in several cases of interstitial deletions of 3p is sensorineural hearing loss, which has been attributed to haploinsufficiency of the MITF gene (OMIM 156845) at 3p13p14.1, a gene considered causal for Waardenberg syndrome Type 2A (WS2A) hearing loss [Nobukuni, 1996] . Full or partial gene deletions and truncating mutations in MITF have been previously described as disease-causing for WS2A, an autosomal dominant disorder [Milunsky et al., 2007; Pingault et al., 2010] . Both FOXP1 and MITF are genes likely to exhibit haploinsufficiency based on their DECIPHER haploinsufficiency scores of 0.13 and 0.97, respectively. A second database ClinGen (https://www.ncbi.nlm.nih. gov/projects/dbvar/clingen) assigns a score of 3 for both genes. This score provides a loss-of-function rating from 0 to 3, with higher ratings reflecting increasing levels of evidence that suggest dosage sensitivity is related to a given phenotype. Inclusion of MITF within a patient's deletion further underscores the need for careful screening and sequential developmental follow-up and intervention for these affected patients.
PROK2
This gene encodes prokineticin 2, a rhythmically expressed protein by the suprachiasmatic nucleus circadian clock that appears to have a developmental role in neuronal migration. Both homozygous and heterozygous point mutations in PROK2 have been associated with hypogonadotropic hypogonadism type 4 with or without anosmia, which is part of the Kallmann syndrome disease spectrum (OMIM 610628). Of note, putative heterozygous truncating mutations have been reported, supporting a haploinsufficiency mechanism of disease.
ATXN7
This gene encodes ataxin 7, a transcription factor that plays a significant role in chromatin remodeling. Alterations in ATXN7 are associated with the autosomal dominant neurodegenerative disorder spinocerebellar ataxia 7, an adult-onset disorder that features progressive cerebellar ataxia and pigmentary macular degeneration (OMIM 164500). The mechanism of disease is an unstable expansion of a (CAG) n repeat from a range of 7-17 repeats in normal alleles with variable expansion up to 38-130 repeats in affected patients. As described in other translated polyglutamine triplet repeat disorders, the repeat tracts are unstable with transmission, and the expansion is associated with anticipation seen in subsequent affected generations. There is striking gonadal instability upon paternal transmission. However, haploinsufficiency of ATXN7 caused by a 3p14 deletion has not been associated with this disorder or with any other known clinical entity to date.
FHIT
The fragile histidine triad or FHIT gene encodes an AP3A hydrolase and was initially identified by its location at a renal cell carcinoma t(3; 8) breakpoint. It is known to span the chromosome 3p14 fragile site, FRA3B [Ohta et al., 1996] . Subsequently, a 200 to 300-kb region including FRA3B was found to be homozygously deleted in multiple tumor cell lines with aberrant FHIT transcripts found in up to 50% of esophageal, colon, and stomach cancers [Ohta et al., 1996] . Somatic mutations of FHIT have also been described in several other tumors (OMIM 601153), though to date, constitutional alterations in FHIT have not been associated with a known developmental phenotype. In addition, there have not been reports of a significantly increased cancer risk in patients with chromosome 3p14 deletions.
The varied deletions described in patients with 3p deletion syndromes include other genes, many of which have not yet been associated with a specific human disorder. It will be important to determine the contribution of these other potential neurodevelopmental genes toward DD and ID. Genes that are found in the deletions of multiple patients include CADPS , CNTN3 , FEZF2 , PDZRN3 , MAGI1 , and PRICKLE2 [Tao et al., 2011; Schwaibold et al., 2013; de la Hoz et al., 2015; Dimitrov et al., 2015] . To date, they are not clearly associated with a clinical phenotype nor are they designated OMIM morbid genes, but their tissue distribution and putative function make them interesting candidates for future studies and genotypephenotype correlations.
Conclusion
Overall, the recent adoption of high-density oligo-SNP CMA has led to the increased identification of cases of chromosome 3p13p14 deletion syndrome. A significant number of these deletions result from complex rearrangements, particularly insertions, which can be found in a balanced state in a carrier parent and prompts the use of structural cytogenetic techniques to identify them. The phenotypes, while varied, do consistently show neurodevelopmental effects, and several specific genes have been determined to be responsible for key clinical features in the patients. Further studies of the underlying structure of the region and examination of the breakpoints of the complex rearrangements that result in 3p deletions may aid in better understanding their genomic mechanisms. Likewise, functional studies of the less well-studied genes located in the deleted intervals can help to elucidate their roles in patient phenotypes and help guide better clinical management and treatment.
